Population-based strategies for Helicobacter pylori-associated disease management: A Japanese perspective

Expert Review of Gastroenterology and Hepatology

Volumn 4, Issue 2, 2010, Pages 149-156

  Shiota, Seiji ^a   Murakami, Kazunari ^a   Fujioka, Toshio ^a   Yamaoka, Yoshio ^a,b  

^a OITA UNIVERSITY   (Japan)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Guideline; Helicobacter pylori; Management; Resistance; Treatment

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ANTIBIOTIC RESISTANCE; ATROPHIC GASTRITIS; CHRONIC URTICARIA; DRUG MEGADOSE; DYSPEPSIA; ENDOSCOPIC MUCOSAL RESECTION; ERADICATION THERAPY; GASTRIC HYPERPLASTIC POLYP; GASTRODUODENAL ULCER; HELICOBACTER INFECTION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION CONTROL; IRON DEFICIENCY ANEMIA; JAPANESE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PRACTICE GUIDELINE; REFLUX ESOPHAGITIS; REVIEW; STOMACH CANCER; STOMACH POLYP;

ANTI-BACTERIAL AGENTS; GASTRITIS, ATROPHIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; JAPAN; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; STOMACH NEOPLASMS;

EID: 77950493976     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.10.7     Document Type: Review

References (59)

1. Graham D, Adam E, Reddy G et al. Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. Dig. Dis. Sci. 36(8), 1084-1088 (1991).
2. Graham D, Malaty H, Evans D, Evans DJ, Klein P, Adam E. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 100(6), 1495-1501 (1991).
3. Karita M, Teramukai S, Matsumoto S. Risk of Helicobacter pylori transmission from drinking well water is higher than that from infected intrafamilial members in Japan. Dig. Dis. Sci. 48(6), 1062-1067 (2003). (Pubitemid 36667827)
4. Asaka M, Kimura T, Kudo M et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 102(3), 760-766 (1992).
5. Graham D, Reddy S. Rapid detection of anti-Helicobacter pylori IgG in urine using immunochromatography. Aliment. Pharmacol. Ther. 15(5), 699-702 (2001). (Pubitemid 32385875)
6. Kumagai T, Malaty H, Graham D et al. Acquisition versus loss of Helicobacter pylori infection in Japan: results from an 8-year birth cohort study. J. Infect. Dis. 178(3), 717-721 (1998). (Pubitemid 28397219)
7. Japanese Society for Helicobacter Research Committee on Guidelines. Guidelines for the management of Helicobacter pylori infection in Japan. J. Jpn Soc. Helicobacter Res. 1(Suppl. 1), 1-12 (2000).
8. Asaka M, Satoh K, Sugano K et al. Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter 6(3), 177-186 (2001). (Pubitemid 32843601)
9. Japanese Society for Helicobacter Research Committee on Guidelines. Guidelines for the management of Helicobacter pylori infection in Japan. Revised edition. J. Jpn Soc. Helicobacter Res. 4 (Suppl. 1), 1-15 (2003).
10. Fujioka T, Yoshiiwa A, Okimoto T, Kodama M, Murakami K. Guidelines for the management of Helicobacter pylori infection in Japan: current status and future prospects. J. Gastroenterol. 42(Suppl. 17), 3-6 (2003). (Pubitemid 46140355)
11. Japanese Society for Helicobacter Research Committee on Guidelines. Guidelines for the management of Helicobacter pylori infection in Japan. Revised edition. J. Jpn Soc. Helicobacter Res. 10(Suppl. 1), 1-25 (2009).
12. Fukase K, Kato M, Kikuchi S et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372(9636), 392-397 (2008).
13. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 272(1), 65-69 (1994). (Pubitemid 24195449)
14. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 345(11), 784-789 (2001).
15. Wotherspoon A, Ortiz-Hidalgo C, Falzon M, Isaacson P. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 338(8776), 1175-1176 (1991).
16. D'Elios M, Appelmelk B, Amedei A, Bergman M, Del Prete G. Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends Mol. Med. 10(7), 316-323 (2004). (Pubitemid 38881520)
17. Gisbert J, Khorrami S, Carballo F, Calvet X, Gené E, Dominguez-Muñoz J. H. pylori eradication therapy vs antisecretory noneradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst. Rev. CD004062 (2004). (Pubitemid 38445423)
18. Miwa H, Sakaki N, Sugano K et al. Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication: a multicenter study of 4940 patients. Helicobacter 9(1), 9-16 (2004). (Pubitemid 38250062)
19. Lai K, Lau C, Ip W et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment. Pharmacol. Ther. 17(6), 799-805 (2003). (Pubitemid 36418877)
20. Vergara M, Catalán M, Gisbert J, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment. Pharmacol. Ther. 21(12), 1411-1418 (2005). (Pubitemid 40874157)
21. Lai K, Lam S, Chu K et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med. 346(26), 2033-2038 (2002). (Pubitemid 34680594)
22. Lai K, Lam S, Chu K et al. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users - a randomized trial. Aliment. Pharmacol. Ther. 18(8), 829-836 (2003). (Pubitemid 37323649)
23. Stolte M, Eidt S. Healing gastric MALT lymphomas by eradicating H. pylori? Lancet 342(8871), 568 (1993). (Pubitemid 23259228)
24. Wotherspoon A, Doglioni C, Diss T et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342(8871), 575-577 (1993). (Pubitemid 23259233)
25. Bayerdörffer E, Neubauer A, Rudolph B et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid
26. tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 345(8965), 1591-1594 (1995).
27. Inagaki H, Nakamura T, Li C et al. Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter pylori eradication and detection of API2-MALT1 fusion. Am. J. Surg. Pathol. 28(12), 1560-1567 (2004). (Pubitemid 39564960)
28. Gasbarrini A, Franceschi F, Tartaglione R, LandolfiR, Pola P, Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 352(9131), 878 (1998). (Pubitemid 28416725)
29. Franchini M, Cruciani M, Mengoli C, Pizzolo G, Veneri D. Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. J. Antimicrob. Chemother. 60(2), 237-246 (2007). (Pubitemid 47243869)
30. Ando K, Shimamoto T, Tauchi T et al. Can eradication therapy for Helicobacter pylori really improve the thrombocytopenia in idiopathic thrombocytopenic purpura? Our experience and a literature review. Int. J. Hematol. 77(3), 239-244 (2003). (Pubitemid 37121849)
31. Fujimura K, Kuwana M, Kurata Y et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int. J. Hematol. 81(2), 162-168 (2005). (Pubitemid 40270991)
32. Sato R, Murakami K, Watanabe K et al. Effect of Helicobacter pylori eradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura. Arch. Intern. Med. 164(17), 1904-1907 (2004). (Pubitemid 39274361)
33. Everhart J, Kruszon-Moran D, Perez-Perez G, Tralka T, McQuillan G. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J. Infect. Dis. 181(4), 1359-1363 (2000). (Pubitemid 30252540)
34. Michel M, Khellaf M, Desforges L et al. Autoimmune thrombocytopenic Purpura and Helicobacter pylori infection. Arch. Intern. Med. 162(9), 1033-1036 (2002). (Pubitemid 34492533)
35. Takahashi T, Yujiri T, Tanizawa Y. Helicobacter pylori and chronic ITP: the discrepancy in the clinical responses to eradication therapy might be due to differences in the bacterial strains. Blood 104(2), 594 (2004). (Pubitemid 38900047)
36. Byrne M, Kerrigan S, Corcoran P et al. Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology 124(7), 1846-1854 (2003). (Pubitemid 36666780)
37. Veneri D, De Matteis G, Solero P et al. Analysis of B- and T-cell clonality and HLA class II alleles in patients with idiopathic thrombocytopenic purpura: correlation with Helicobacter pylori infection and response to eradication treatment. Platelets 16(5), 307-311 (2005). (Pubitemid 40943926)
38. Uemura N, Mukai T, Okamoto S et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol. Biomarkers Prev. 6(8), 639-642 (1997). (Pubitemid 27342688)
39. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 12(Suppl. 2), 32-38 (2007). (Pubitemid 350076224)
40. Ohkusa T, Takashimizu I, Fujiki K et al. Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial. Ann. Intern. Med. 129(9), 712-715 (1998). (Pubitemid 28507144)
41. Ji F, Wang Z, Ning J, Wang Q, Chen J, Li Y. Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial. World J. Gastroenterol. 12(11), 1770-1773 (2006).
42. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56(6), 772-781 (2007). (Pubitemid 46854190)
43. Miwa H, Hirai S, Nagahara A et al. Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. Aliment. Pharmacol. Ther. 14(3), 317-324 (2000). (Pubitemid 30145320)
44. Kamada T, Haruma K, Hata J et al. The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. Aliment. Pharmacol. Ther. 18(2), 245-252 (2003). (Pubitemid 36951662)
45. Azuma T, Ito Y, Suto H et al. The effect of Helicobacter pylori eradication therapy on dyspepsia symptoms in industrial workers in Japan. Aliment. Pharmacol. Ther. 15(6), 805-811 (2001). (Pubitemid 32500426)
46. Suzuki H, Masaoka T, Sakai G, Ishii H, Hibi T. Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy. J. Gastroenterol. Hepatol. 20(11), 1652-1660 (2005). (Pubitemid 43961068)
47. Shiota S, Murakami K, Takayama A et al. Evaluation of Helicobacter pylori status and endoscopic findings among new outpatients with dyspepsia in Japan. J. Gastroenterol. 44(9), 930-934 (2009).
48. Kawanishi M. Development of reflux esophagitis following Helicobacter pylori eradication. J. Gastroenterol. 40(11), 1024-1028 (2005). (Pubitemid 43055285)
49. Sasaki A, Haruma K, Manabe N, Tanaka S, Yoshihara M, Chayama K. Long-term observation of reflux oesophagitis developing after Helicobacter pylori eradication therapy. Aliment. Pharmacol. Ther. 17(12), 1529-1534 (2003). (Pubitemid 36831444)
50. Tsukada K, Miyazaki T, Katoh H et al. The incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori. Eur. J. Gastroenterol. Hepatol. 17(10), 1025-1028 (2005). (Pubitemid 41423994)
51. Chey W. Proton pump inhibitors and the urea breath test: how long is long enough? Am. J. Gastroenterol. 92(4), 720-721 (1997). (Pubitemid 27184409)
52. Laine L, Estrada R, Trujillo M, Knigge K, Fennerty M. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann. Intern. Med. 129(7), 547-550 (1998). (Pubitemid 28460295)
53. Graham D, Opekun A, Hammoud F et al. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am. J. Gastroenterol. 98(5), 1005-1009 (2003). (Pubitemid 36733759)
54. Kuwayama H, Asaka M, Sugiyama T et al. Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan. Aliment. Pharmacol. Ther. 25(9), 1105-1113 (2007). (Pubitemid 46587695)
55. Murakami K, Sato R, Okimoto T et al. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment. Pharmacol. Ther. 17(1), 119-123 (2003). (Pubitemid 36140441)
56. Shimoyama T, Fukuda S, Mikami T, Fukushi M, Munakata A. Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population. J. Gastroenterol. 39(10), 927-930 (2004). (Pubitemid 39490168)
57. Fukuda S, Shimoyama T, Tanaka M, Nakasato F, Fukushi M, Munakata A. Duration of the metronidazole-containing regimen for eradication of Helicobacter pylori infection in northern Japan. Jpn J. Infect. Dis. 59(6), 367-369 (2006). (Pubitemid 46040414)
58. Murakami K, Okimoto T, Kodama M, Sato R, Watanabe K, Fujioka T. Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection. J. Clin. Gastroenterol. 42(2), 139-142 (2008).
59. Kobayashi I, Murakami K, Kato M et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J. Clin. Microbiol. 45(12), 4006-4010 (2007). (Pubitemid 350274884)